Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00833261 · ClinicalTrials.gov registry record · Phase 2

Nab-Paclitaxel, Cetuximab, Cisplatin, and Radiation Therapy in Treating Patients With Recurrent Head and Neck Cancer

A Phase 2 study of Head and Neck Cancer, sponsored by University of Texas Southwestern Medical Center.

Completed
Registry status
Phase 2
Development phase
37
Enrollment target
4
Study locations

NCT00833261 is a Phase 2 study of Head and Neck Cancer that has completed, run by University of Texas Southwestern Medical Center. The registered enrollment target is 37 participants, below the 261-participant average among 250 other Head and Neck Cancer trials with a reported enrollment target (86% lower). The trial reports 4 study locations across 3 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00833261, a Phase 2 study of Head and Neck Cancer, has completed, sponsored by University of Texas Southwestern Medical Center.

COMPLETED
Registry status
Phase 2
Development phase
37 participants
Enrollment target
4
Study locations

Study Summary

RATIONALE: Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill tumor cells. Giving cetuximab and cisplatin together with radiation therapy may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving cetuximab and cisplatin together with radiation therapy works in treating patients with recurrent head and neck cancer.

Conditions Studied

Head and Neck Cancer

Interventions

  • DRUG cetuximab
  • DRUG Nab-Paclitaxel
  • DRUG cisplatin
  • RADIATION intensity-modulated radiation therapy

Study Locations (4)

Texas

  • Baylor Research Institute - Dallas
  • University of Texas Southwestern Medical Center - Dallas - Dallas

Ohio

  • University Hospitals of Cleveland - Cleveland

Wisconsin

  • Medical College of Wisconsin - Milwaukee

Trial Details

FieldValue
Enrollment Target 37 participants
Start Date 2008-12
Est. Completion 2016-05
Phase Phase 2

Sponsor

University of Texas Southwestern Medical Center

837 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00833261

The ClinicalTrials.gov registry entry for NCT00833261 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 37 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 261-participant average among 250 other Head and Neck Cancer trials with a reported enrollment target (86% lower). The listed sponsor is University of Texas Southwestern Medical Center, which has 837 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Head and Neck Cancer appearing as the primary indexed condition, and to 4 interventions - of which cetuximab is the first listed.

NCT00833261 reports 4 study locations spanning 3 distinct geographic areas - top geographies include Texas, Ohio, Wisconsin.

Frequently Asked Questions

What is clinical trial NCT00833261 about?

NCT00833261 is a clinical study titled "Nab-Paclitaxel, Cetuximab, Cisplatin, and Radiation Therapy in Treating Patients With Recurrent Head and Neck Cancer". RATIONALE: Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Drugs used in chemotherapy, such as cisplatin, work in differ...

What is the current status of trial NCT00833261?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 37 participants. The study started on 2008-12. Estimated completion is 2016-05.

What conditions does trial NCT00833261 study?

This clinical trial studies the following conditions: Head and Neck Cancer.

What interventions are being tested in trial NCT00833261?

The interventions under investigation include: cetuximab (DRUG), Nab-Paclitaxel (DRUG), cisplatin (DRUG), intensity-modulated radiation therapy (RADIATION).

Who is sponsoring clinical trial NCT00833261?

This trial is sponsored by University of Texas Southwestern Medical Center, which has 837 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00833261 being conducted?

This trial has 4 study locations across Ohio, Texas, Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Head and Neck Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Head and Neck Cancer

All registered trials for this condition

Ohio

All trials with a study site in Ohio

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.